Crossmark

Redifferentiation — a 'new' option for 131I-negative DTC

Crossref DOI link: https://doi.org/10.1038/nrendo.2016.182

Published Online: 2016-11-11

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Verburg, Frederik A.

Luster, Markus
License Information

Text and Data Mining valid from 2016-11-11
More Information

Article History

First Online: 11 November 2016

Competing interests

: F.A.V. has been a consultant for Bayer Healthcare and Sanofi Genzyme and received speaker honoraria from Diasorin and Sanofi Genzyme. M.L. has been a consultant for AstraZeneca, Bayer Healthcare, Sanofi Genzyme and Sobi and received speaker honoraria and research support from Henning, Sanofi Genzyme and Merck.